[{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"0ad91159-5e74-4841-9bb6-f71f53c01cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07181720","created_at":"2025-09-20T07:06:00.818Z","updated_at":"2025-09-20T07:06:00.818Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial","source_id_and_acronym":"NCT07181720","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-09-18"},{"id":"b0935c07-a451-47fa-8f96-112ab5dc4cae","acronym":"TATC","url":"https://clinicaltrials.gov/study/NCT07138261","created_at":"2025-08-30T14:02:24.019Z","updated_at":"2025-08-30T14:02:24.019Z","phase":"","brief_title":"Taiwanese Anaplastic Thyroid Cancer Registry","source_id_and_acronym":"NCT07138261 - TATC","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/30/2035","primary_completion_date":" 12/30/2035","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-08-22"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"0a783bcc-4ad7-4844-9ff8-1c57f587c024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04759911","created_at":"2021-02-18T22:55:11.009Z","updated_at":"2025-02-25T16:53:32.021Z","phase":"Phase 2","brief_title":"Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer","source_id_and_acronym":"NCT04759911","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/26/2021","start_date":" 02/26/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-04"},{"id":"e9470dbe-6c8c-46dd-ae0a-0bcfc3baa4c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04420754","created_at":"2021-01-18T21:18:07.734Z","updated_at":"2025-02-25T17:24:41.108Z","phase":"Phase 1","brief_title":"Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer","source_id_and_acronym":"NCT04420754","lead_sponsor":"AffyImmune Therapeutics, Inc.","biomarkers":" BRAF • ICAM1","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF • ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AIC100"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 08/04/2026","primary_completion_date":" 08/04/2026","study_txt":" Completion: 08/04/2030","study_completion_date":" 08/04/2030","last_update_posted":"2025-01-31"},{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"69622ca4-3967-4dd1-94fb-bb4cbf2391b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03181100","created_at":"2021-01-17T18:00:20.904Z","updated_at":"2024-07-02T16:35:06.482Z","phase":"Phase 2","brief_title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03181100","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-05-02"},{"id":"5b055811-137d-4883-877e-09237bc8eba9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06374602","created_at":"2024-04-18T16:47:43.205Z","updated_at":"2024-07-02T16:35:08.956Z","phase":"Phase 2","brief_title":"Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer","source_id_and_acronym":"NCT06374602","lead_sponsor":"Saint Petersburg State University, Russia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/25/2024","start_date":" 03/25/2024","primary_txt":" Primary completion: 03/25/2026","primary_completion_date":" 03/25/2026","study_txt":" Completion: 06/25/2026","study_completion_date":" 06/25/2026","last_update_posted":"2024-04-18"},{"id":"bd4d0e13-8987-4f75-b586-db0b96b6ac26","acronym":"","url":"https://clinicaltrials.gov/study/NCT06362694","created_at":"2024-04-12T14:46:15.420Z","updated_at":"2024-07-02T16:35:09.932Z","phase":"Phase 2","brief_title":"Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy","source_id_and_acronym":"NCT06362694","lead_sponsor":"Saint Petersburg State University, Russia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/25/2024","start_date":" 03/25/2024","primary_txt":" Primary completion: 03/25/2026","primary_completion_date":" 03/25/2026","study_txt":" Completion: 06/25/2026","study_completion_date":" 06/25/2026","last_update_posted":"2024-04-12"},{"id":"e33f740e-9d52-4be5-afc3-40dc9b4c1c85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04552769","created_at":"2021-01-18T21:46:05.370Z","updated_at":"2024-07-02T16:35:18.129Z","phase":"Phase 2","brief_title":"Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer","source_id_and_acronym":"NCT04552769","lead_sponsor":"Stanford University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/10/2020","start_date":" 09/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-22"},{"id":"918ddae7-2ff1-4ee0-9113-6762c5e8dfb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579757","created_at":"2021-01-18T21:51:28.003Z","updated_at":"2024-07-02T16:35:19.961Z","phase":"Phase 1/2","brief_title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04579757","lead_sponsor":"Hutchmed","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-02-09"},{"id":"735c4cb6-c266-4b82-980b-643443a3b6c5","acronym":"SETHY","url":"https://clinicaltrials.gov/study/NCT06235216","created_at":"2024-02-01T00:20:51.908Z","updated_at":"2024-07-02T16:35:21.472Z","phase":"Phase 2","brief_title":"Sacituzumab govitEcan in THYroid Cancers","source_id_and_acronym":"NCT06235216 - SETHY","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-01-31"},{"id":"b93c89b1-0be1-4382-a0ed-b574fd202393","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT05768178","created_at":"2023-03-14T14:01:47.347Z","updated_at":"2024-07-02T16:35:31.784Z","phase":"Phase 2/3","brief_title":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","source_id_and_acronym":"NCT05768178 - DETERMINE","lead_sponsor":"Cancer Research UK","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2023-10-25"},{"id":"1bdd6f63-5019-4415-8262-b36f6b64000b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592484","created_at":"2021-01-19T20:28:45.384Z","updated_at":"2024-07-02T16:35:56.190Z","phase":"Phase 1/2","brief_title":"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors","source_id_and_acronym":"NCT04592484","lead_sponsor":"Codiak BioSciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exoSTING"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 08/03/2022","primary_completion_date":" 08/03/2022","study_txt":" Completion: 12/23/2022","study_completion_date":" 12/23/2022","last_update_posted":"2023-02-08"},{"id":"eedba941-2b97-4580-b96f-8e9754e3ed63","acronym":"","url":"https://clinicaltrials.gov/study/NCT05659186","created_at":"2022-12-21T15:59:12.203Z","updated_at":"2024-07-02T16:35:58.812Z","phase":"Phase 2","brief_title":"PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer","source_id_and_acronym":"NCT05659186","lead_sponsor":"West China Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2022-12-21"},{"id":"0dff7f04-3f58-49c6-8eb8-ea8e8e1ba046","acronym":"","url":"https://clinicaltrials.gov/study/NCT05453799","created_at":"2022-07-12T10:54:40.764Z","updated_at":"2024-07-02T16:36:04.939Z","phase":"Phase 2","brief_title":"Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT05453799","lead_sponsor":"Northwestern University","biomarkers":" BRAF • CD4","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2022-08-24"},{"id":"f6309da0-cacf-45b1-9ecd-688a82d8475d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02404441","created_at":"2021-01-18T11:28:49.090Z","updated_at":"2024-07-02T16:36:06.170Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PDR001 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT02404441","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK translocation","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 04/27/2015","start_date":" 04/27/2015","primary_txt":" Primary completion: 07/21/2020","primary_completion_date":" 07/21/2020","study_txt":" Completion: 07/21/2020","study_completion_date":" 07/21/2020","last_update_posted":"2022-08-03"},{"id":"29fd7d6f-1350-443f-bd63-34a130b6937b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688608","created_at":"2021-01-18T13:06:44.688Z","updated_at":"2025-02-25T16:04:21.112Z","phase":"Phase 2","brief_title":"Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer","source_id_and_acronym":"NCT02688608","lead_sponsor":"Saad A Khan","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-02-10"},{"id":"91d09991-0ff4-45a4-91a3-8c453d5c199d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574817","created_at":"2021-01-18T21:50:30.903Z","updated_at":"2024-07-02T16:36:40.443Z","phase":"Phase 2","brief_title":"Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)","source_id_and_acronym":"NCT04574817","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 05/30/2022","primary_completion_date":" 05/30/2022","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2020-10-05"},{"id":"0a10d695-9eda-4060-8645-6fd512a72966","acronym":"","url":"https://clinicaltrials.gov/study/NCT03211117","created_at":"2021-01-18T15:50:14.583Z","updated_at":"2024-07-02T16:36:47.701Z","phase":"Phase 2","brief_title":"Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer","source_id_and_acronym":"NCT03211117","lead_sponsor":"Mayo Clinic","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • doxorubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 02/12/2018","primary_completion_date":" 02/12/2018","study_txt":" Completion: 03/28/2019","study_completion_date":" 03/28/2019","last_update_posted":"2020-03-25"},{"id":"a83b7e71-f3bb-41fd-84d4-90b73ff208a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02289144","created_at":"2021-01-18T10:47:25.802Z","updated_at":"2025-02-25T15:42:03.152Z","phase":"Phase 2","brief_title":"Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer","source_id_and_acronym":"NCT02289144","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-07-30"},{"id":"af1012dd-c83c-42c5-afc7-ffcd0bcc1e95","acronym":"","url":"https://clinicaltrials.gov/study/NCT02114658","created_at":"2021-01-18T09:47:06.847Z","updated_at":"2025-02-25T17:07:25.629Z","phase":"Phase 2","brief_title":"Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients","source_id_and_acronym":"NCT02114658","lead_sponsor":"Bayer","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/15/2014","start_date":" 04/15/2014","primary_txt":" Primary completion: 02/23/2015","primary_completion_date":" 02/23/2015","study_txt":" Completion: 08/02/2016","study_completion_date":" 08/02/2016","last_update_posted":"2017-08-03"}]